- Home
- SEER vs HLVX Comparison
SEER vs HLVX Comparison
Compare SEER & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEER
- HLVX
- Stock Information
- Founded
- SEER 2017
- HLVX 2020
- Country
- SEER United States
- HLVX United States
- Employees
- SEER N/A
- HLVX N/A
- Industry
- SEER Medicinal Chemicals and Botanical Products
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- SEER Health Care
- HLVX Health Care
- Exchange
- SEER Nasdaq
- HLVX Nasdaq
- Market Cap
- SEER 113.8M
- HLVX 104.3M
- IPO Year
- SEER 2020
- HLVX 2022
- Fundamental
- Price
- SEER $2.04
- HLVX $2.10
- Analyst Decision
- SEER
- HLVX Hold
- Analyst Count
- SEER 0
- HLVX 1
- Target Price
- SEER N/A
- HLVX $2.00
- AVG Volume (30 Days)
- SEER 134.9K
- HLVX 826.9K
- Earning Date
- SEER 11-05-2025
- HLVX 11-06-2025
- Dividend Yield
- SEER N/A
- HLVX N/A
- EPS Growth
- SEER N/A
- HLVX N/A
- EPS
- SEER N/A
- HLVX N/A
- Revenue
- SEER $16,288,000.00
- HLVX N/A
- Revenue This Year
- SEER $27.77
- HLVX N/A
- Revenue Next Year
- SEER $20.28
- HLVX N/A
- P/E Ratio
- SEER N/A
- HLVX N/A
- Revenue Growth
- SEER 10.52
- HLVX N/A
- 52 Week Low
- SEER $1.62
- HLVX $1.34
- 52 Week High
- SEER $2.63
- HLVX $2.17
- Technical
- Relative Strength Index (RSI)
- SEER 46.20
- HLVX 54.38
- Support Level
- SEER $1.97
- HLVX $2.07
- Resistance Level
- SEER $2.10
- HLVX $2.11
- Average True Range (ATR)
- SEER 0.05
- HLVX 0.02
- MACD
- SEER 0.00
- HLVX -0.00
- Stochastic Oscillator
- SEER 43.75
- HLVX 54.55
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.